Work

A Tale of Two Pathways: Renewing the Promise of Anti-CD40L Blockade

Year: 2017

Type: editorial

Abstract: A new Fc-silent anti-human CD154 domain antibody synergizes with conventional immunosuppressants to control renal transplant rejection in nonhuman primates without evidence of thromboembolism, raising the prospect of its combination with approved costimulation-blocking agents in the clinic. See the article from Kim et al on page 1182.

Source: American Journal of Transplantation

DOI: 10.1111/ajt.14217

Authors: A.W. Thomson, M.B. Ezzelarab

Institution: University of Pittsburgh

Language: English

Topic: Renal Transplantation Outcomes and Treatments

Subfield: Transplantation

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,300